Design and synthesis of 2- and 3-substituted-3-phenylpropyl analogs of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine: Role of amino, fluoro, hydroxyl, methoxyl, methyl, methylene, and oxo substituents on affinity for the dopamine and serotonin transporters

Journal of Medicinal Chemistry

Volumn 51, Issue 9, 2008, Pages 2795-2806

  Hsin, Ling Wei ^a   Chang, Li Te ^a   Rothman, Richard B ^c   Dersch, Christina M ^c   Jacobson, Arthur E ^b   Rice, Kenner C ^b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 BENZYL ALLYL) 4 [2 (DIPHENYLMETHOXY)ETHYL]PIPERAZINE; 1 (2 BENZYL ALLYL) 4 [2 [BIS(4FLUOROPHENYL)METHOXY]ETHYL]PIPERAZINE; 1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLPROPYL)PIPERAZINE; 1 [2 (DIPHENYLMETHOXY)ETHYL] 4 (3 PHENYL BUR 3 ENYL)PIPERAZINE; 1 [2 [BIS(4 FLUOROPHENYL)METHOXY]ETHYL] 4 (2 AMINO 3 PHENYLPROPYL)PIPERAZINE; 1 [2 [BIS(4 FLUOROPHENYL)METHOXY]ETHYL] 4 (2 FLUORO 3 PHENYLPROPYL)PIPERAZINE; 1 [2 [BIS(4 FLUOROPHENYL)METHOXY]ETHYL] 4 (2 METHYL 3 PHENYLPROPYL)PIPERAZINE; 1 [2 [BIS(4 FLUOROPHENYL)METHOXY]ETHYL] 4 [2 (TERT BUTYLOXYCARBONYLAMINO) 3 PHENYLPROPYL]PIPERAZINE; 1 [4 [2 (DIPHENYLMETHOXY)ETHYL]PIPERAZINYL] 2 METHYL 3 PHENYLPROPAN 2 OL; 1 [4 [2 (DIPHENYLMETHOXY)ETHYL]PIPERAZINYL] 3 PHENYLPROPAN 2 ONE; 1 [4 [2 [BIS(4 FLUOROPHENYL)METHOXY]ETHYL]PIPERAZINYL] 2 METHOXY 3 PHENYLPROPAN 1 ONE; 1 [4 [2 [BIS(4 FLUOROPHENYL)METHOXY]ETHYL]PIPERAZINYL] 2 METHYL 3 PHENYLPROPAN 2 OL; 1 [4 [2 [BIS(4 FLUOROPHENYL)METHOXY]ETHYL]PIPERAZINYL] 2 PHENYLPROPAN 1 ONE; 1 [4 [2 [BIS(4 FLUOROPHENYL)METHOXY]ETHYL]PIPERAZINYL] 3 PHENYLPROPAN 2 ONE; 2 [4 [2 (DIPHENYLMETHOXY]ETHYL]PIPERAZINYL] 1 PHENYLETHANONE; 2 [4 [2 [BIS(4 FLUOROPHENYL)METHOXY]ETHYL]PIPERAZINYL] 1 PHENYLETHANONE; 2 BENZYL 1 [4 [2 (DIPHENYLMETHOXY)ETHYL]PIPERAZINYL]PROPENONE; 2 BENZYL 1 [4 [2 [BIS(4 FLUOROPHENYL)METHOXY]ETHYL]PIPERAZINYL]PROPENONE; 4 [4 [2 (DIPHENYLMETHOXY)ETHYL]PIPERAZINYL] 2 PHENYLBUTAN 2 OL; 4 [4 [2 [BIS(4 FLUOROPHENYL)METHOXY]ETHYL]PIPERAZINYL] 2 PHENYLBUTAN 2 OL; DOPAMINE TRANSPORTER; SEROTONIN TRANSPORTER; VANOXERINE;

ARTICLE; BINDING AFFINITY; DRUG DESIGN; DRUG SYNTHESIS; ELECTRON; STEREOSPECIFICITY; STRUCTURE ACTIVITY RELATION;

DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; PIPERAZINES; RADIOLIGAND ASSAY; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 42949170451     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701270n     Document Type: Article

References (45)

1. Johanson, C. E.; Fischman, M. W. The Pharmacology of Cocaine Related to Its Abuse. Pharmacol. Rev. 1989, 41, 3-52.
2. Musto, D. F. Opium, Cocaine, and Marijuana in American History. Sci. Am. 1991, 265, 40-47.
3. McCoy, C. B.; Metsch, L. R.; Inciardi, J. A.; Anwyl, R. S.; Wingerd, J.; Bletzer, K. Sex, Drugs, and the Spread of HIV/AIDS in Belle Glade, Florida. Med. Anthrop. Quart. 1996, 10, 83-93.
4. Hser, Y.-I.; Chih-Ping, C.; Hoffman, V.; Anglin, M. D. Cocaine Use and High-Risk Sexual Behavior among STD Clinic Patients. Sex. Transm. Dis. 1999, 26, 82-86.
5. Mitscher, L. A.; Baker, W. Tuberculosis: A Search for Novel Therapy Starting with Natural Products. Med. Res. Rev. 1998, 18, 363-374.
6. Volkow, N. D.; Wang, G. J.; Fischman, M. W.; Foltin, R. W.; Fowler, J. S.; Abumrad, N. N.; Vitkun, S.; Logan, J.; Gatley, S. J.; Pappas, N.; Hitzemann, R.; Shea, C. E. Relationship between Subjective Effects of Cocaine and Dopamine Transporter Occupancy. Nature 1997, 386, 827-830.
7. Volkow, N. D.; Wang, G. J.; Fowler, J. S.; Logan, J.; Gatley, S. J.; Hitzemann, R.; Chen, A. D.; Dewey, S. L.; Pappas, N. Decreased Striatal Dopaminergic Responsiveness in Detoxified Cocaine-Dependent Subjects. Nature 1997, 386, 830-833.
8. Self, D. W.; Nestler, E. J. Molecular Mechanisms of Drug Reinforcement and Addiction. Annu. Rev. Neurosci. 1995, 18, 463-495.
9. Mash, D. C.; Pablo, J. P.; Ouyang, Q.; Hearn, W. L.; Izenwasser, S. Dopamine Transport Function Is Elevated in Cocaine Users. J. Neurochem. 2002, 81, 292-300.
10. Wise, R. A. Catecholamine Theories of Reward. A Critical Review. Brain Res. 1978, 152, 215-247.
11. Kuhar, M. J.; Ritz, M. C.; Boja, J. W. The Dopamine Hypothesis of the Reinforcing Properties of Cocaine. Trends Neurosci. 1991, 14, 299-302.
12. Ritz, M. C.; Lamb, R. J.; Goldberg, S. R.; Kuhar, M. J. Cocaine Receptors on Dopamine Transporters Are Related to Self-Administration of Cocaine. Science 1987, 237, 1219-1223.
13. Rothman, R. B. High Affinity Dopamine Reuptake Inhibitors as Potential Cocaine Antagonists: A Strategy for Drug Development. Life Sci. 1990, 46, PL217-PL221.
14. Greiner, E.; Boos, T. L.; Prisinzano, T.; De Martino, M. G.; Zeglis, B.; Dersch, C. M.; Marcus, J.; Partilla, J. S.; Rothman, R. B.; Jacobson, A. E.; Rice, K. C. Design and Synthesis of Promiscuous High-Affinity Monoamine Transporter Ligands: Unraveling Transporter Selectivity. J. Med. Chem. 2006, 49, 1766-1772.
15. Rothman, R. B.; Baumann, M. H.; Dersch, C. M.; Romero, D. V.; Rice, K. C.; Carroll, F. I.; Partilla, J. S. Amphetamine-Type Central Nervous System Stimulants Release Norepinephrine More Potently Than They Release Dopamine and Serotonin. Synapse 2001, 39, 32-41.
16. Baumann, M. H.; Rothman, R. B. Alterations in Serotonergic Responsiveness During Cocaine Withdrawal in Rats: Similarities to Major Depression in Humans. Biol. Psychiatry 1998, 44, 578-591.
17. Rothman, R. B.; Baumann, M. H. Therapeutic and Adverse Reactions of Serotonin Transporter Substrates. Pharmacol. Ther. 2002, 95, 73-88.
18. Zhou, J.; Zhang, A.; Klass, T.; Johnson, K. M.; Wang, C. Z.; Ye, Y. P.; Kozikowski, A. P. Biaryl Analogues of Conformationally Constrained Tricyclic Tropanes as Potent and Selective Norepinephrine Reuptake Inhibitors: Synthesis and Evaluation of Their Uptake Inhibition at Monoamine Transporter Site. J. Med. Chem. 2003, 46, 1997-2007.
19. Zhao, Y.; Sun, L. Perinatal Cocaine Exposure Reduces Myocardial Norepinephrine Transporter Function in the Neonatal Rat. Neurotoxicol. Teratol. 2004, 26, 443-450.
20. 123I]CIT. Eur. J. Pharmacol. 1991, 200, 369-370.
21. Bouis, F.; Baldwin, R. M.; Kula, N. S.; Baldessarini, R. J.; Innis, R. B.; Tamagnan, G. Synthesis and Monoamine Transporter Affinity of 3′-Analogues of 2β-Carbomethoxy-3-β-(4′-iodophenyl)tropane (β-CIT). Bioorg. Med. Chem. Lett. 2004, 14, 2117-2120.
22. Rocha, B. A.; Scearce-Levie, K.; Lucas, J. J.; Hiroi, N.; Castanon, N.; Crabbe, J. C.; Nestler, E. J.; Hen, R. Increased Vulnerability to Cocaine in Mice Lacking the Serotonin-1β Receptor. Nature 1998, 393, 175-178.
23. Caine, S. B. Cocaine Self-Administration in Dopamine-Transporter Knockout Mice. Nat. Neurosci. 1998, 1, 90-92.
24. Petukhov, P. A.; Zhang, J. R.; Wang, C. Z.; Ye, Y. P.; Johnson, K. M.; Kozikowski, A. P. Synthesis, Molecular Modeling, and Biological Studies of Novel Piperidine-Based Analogues of Cocaine: Evidence of Unfavorable Interactions Proximal to the 3αÑ-Position of the Piperidine Ring. J. Med. Chem. 2004, 47, 3009-3018.
25. Rocha, B. A.; Fumagalli, F.; Gainetdinov, R. R.; Jones, S. R.; Ator, R.; Giros, B.; Miller, G. W.; Caron, G. Cocaine Self-Administration in Dopamine-Transporter Knockout Mice. Nat. Neurosci. 1998, 1, 132-137.
26. Walsh, S. L.; Cunningham, K. A. Serotonergic Mechanisms Involved in the Discrimination Stimulus, Reinforcing and Subjective Effects of Cocaine. Psychopharmacology (Berlin) 1997, 130, 41-58.
27. Howell, L. L.; Carroll, F. I.; Votaw, J. R.; Goodman, M. M.; Kimmel, H. L. Effects of Combined Dopamine and Serotonin Transporter Inhibitors on Cocaine Self-Administration in Rhesus Monkeys. J. Pharmacol. Exp. Ther. 2007, 320, 757-765.
28. Yu, H.; Kim, I. J.; Folk, J. E.; Tian, X. R.; Rothman, R. B.; Baumann, M. H.; Dersch, C. M.; Flippen-Anderson, J. L.; Parrish, D.; Jacobson, A. E.; Rice, K. C. Synthesis and Pharmacological Evaluation of 3-(3,4-Dichlorophenyl)-1- indanamine Derivatives as Nonselective Ligands for Biogenic Amine Transporters. J. Med. Chem. 2004, 47, 2624-2634.
29. Carroll, F. I.; Howell, L. L.; Kuhar, M. J. Pharmacotherapies for Treatment of Cocaine Abuse: Preclinical Aspects. J. Med. Chem. 1999, 42, 2721-2736.
30. Smith, M. P.; Hoepping, A.; Johnson, K. M.; Trzcinska, M.; Kozikowski, A. P. Dopaminergic Agents for the Treatment of Cocaine Abuse. Drug Discovery Today 1999, 4, 322-332.
31. Singh, S. Chemistry, Design, and Structure-Activity Relationship of Cocaine Antagonists. Chem. Rev. 2000, 100, 925-1024.
32. Lewis, D. B.; Zhang, Y.; Prisinzano, T.; Dersch, C. M.; Rothman, R. B.; Jacobson, A. E.; Rice, K. C. Further Exploration of 1-[2-[Bis(4-fluorophenyl) methoxy]ethyl]piperazine (GBR 12909): Role of N-Aromatic, N-Heteroaromatic, and 3-Oxygenated N-Phenylpropyl Substituents on Affinity for the Dopamine and Serotonin Transporter. Bioorg. Med. Chem. Lett. 2003, 13, 1385-1389.
33. Van der Zee, P.; Koger, H. S.; Goojtes, J.; Hespe, W. Aryl 1,4-Dialk(en)ylpiperazines as Selective and Very Potent Inhibitors of Dopamine Uptake. Eur. J. Med. Chem. 1980, 15, 363-370.
34. Lewis, D. B.; Matecka, D.; Zhang, Y.; Hsin, L. W.; Dersch, C. M.; Stafford, D.; Glowa, J. R.; Rothman, R. B.; Rice, K. C. Oxygenated Analogues of 1-[2-(Diphenylmethoxy)ethyl]- and 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3- phenylpropyl)piperazines (GBR 12935 and GBR 12909) as Potential Extended-Action Cocaine-Abuse Therapeutic Agents. J. Med. Chem. 1999, 42, 5029-5042.
35. Glowa, J. R.; Fantegrossi, W. E.; Lewis, D. B.; Matecka, D.; Rice, K. C.; Rothman, R. B. Sustained Decrease in Cocaine-Maintained Responding in Rhesus Monkeys with 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-hydroxyl-3- phenylpropyl)piperazinyl Decanoate, a Long-Acting Ester Derivative of GBR 12909. J. Med. Chem. 1996, 39, 4689-4691.
36. Hsin, L. W.; Dersch, C. M.; Baumann, M. H.; Stafford, D.; Glowa, J. R.; Rothman, R. B.; Jacobson, A. E.; Rice, K. C. Development of Long-Acting Dopamine Transporter Ligands as Potential Cocaine-Abuse Therapeutic Agents: Chiral Hydroxyl-Containing Derivatives of 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3- phenylpropyl)piperazine and 1-[2-(Diphenylmethoxy)ethyl]-4-(3-phenylpropyl) piperazine. J. Med. Chem. 2002, 45, 1321-1329.
37. Hsin, L. W.; Prisinzano, T.; Wilkerson, C. R.; Dersch, C. M.; Horel, R.; Jacobson, A. E.; Rothman, R. B.; Rice, K. C. Synthesis and Dopamine Transporter Affinity of Chiral 1-[2-[Bis(4-fluorophenyl-)methoxy]ethyl]-4-(2-hydroxypropyl) piperazines as Potential Cocaine Abuse Therapeutic Agents. Bioorg. Med. Chem. Lett. 2003, 13, 553-556.
38. 4-Zn Systems by Addition of Lead. J. Org. Chem. 1994, 59, 2668-2670.
39. Jackson, P. F.; Tays, K. L.; Maclin, K. M.; Ko, Y.-S.; Li, W.; Vitharana, D.; Tsukamoto, T.; Stoermer, D.; Lu, X.-C. M.; Wozniak, K.; Slusher, B. S. Design and Pharmacological Activity of Phosphinic Acid Based NAALADase Inhibitors. J. Med. Chem. 2001, 44, 4170-4175.
40. Liu, X.; Hu, E. X.; Tian, X.; Mazur, A.; Ebetino, F. H. Enantioselective Synthesis of Phosphinyl Peptidomimetics via an Asymmetric Michael Reaction of Phosphinic Acids with Acrylate Derivatives. J. Organomet. Chem. 2002, 646, 212-222.
41. Barluenga, J.; Yus, M.; Concellón, J. M.; Bernad, P. Direct One-Pot Synthesis of Terminal Olefins and Deuterio Olefins from Carboxylic Acid Chlorides. J. Org. Chem. 1983, 48, 3116-3118.
42. Gist-Brocades N. V. Piperazine derivatives, and pharmaceutical compositions containing them; Patent application NL 82-02636 19820629, 1984.
43. Howell, L. L.; Czoty, P. W.; Byrd, L. D. Pharmacological Interactions Between Serotonin and Dopamine on Behavior in the Squirrel Monkey. Psychopharmacology (Berlin) 1997, 131, 40-48.
44. Rothman, R. B.; Lewis, B.; Dersch, C.; Xu, H.; Radesca, L.; de Costa, B. R.; Rice, K. C.; Kilburn, R. B.; Akunne, H. C.; Pert, A. Identification of a GBR 12935 Homolog, LR 1111, Which Is over 4000-Fold Selective for the Dopamine Transporter, Relative to Serotonin and Norepinephrine Transporters. Synapse 1993, 14, 34-39.
45. 125I]RTI-55. J. Pharmacol. Exp. Ther. 1994, 270, 296-309.